19-Nor-5-androstenediol
19-Nor-5-androstenediol, also known as estr-5-ene-3β,17β-diol, is a synthetic, orally active anabolic-androgenic steroid (AAS) and a derivative of 19-nortestosterone (nandrolone) that was never introduced for medical use.[1][2][3] It is an androgen prohormone of nandrolone and of other 19-norandrostanes.[1][2][3]
Clinical data | |
---|---|
Other names | Estr-5-ene-3β,17β-diol; 19-Norandrost-5-ene-3β,17β-diol |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H28O2 |
Molar mass | 396.530 g·mol−1 |
3D model (JSmol) | |
| |
|
19-Nor-5-androstenediol, 19-nor-5-androstenedione, and other 19-norandrostane prohormones were considered to be nutritional supplements and were sold over-the-counter in the United States as a result of the Dietary Supplement Health and Education Act of 1994 (DSHEA).[1][2] However, they were banned from sports in 1999 by the International Olympic Committee (IOC) and are currently on the World Anti-Doping Agency (WADA) list of prohibited substances.[1] In 2004, they became controlled substances in the U.S. as a result of the Anabolic Steroid Control Act of 2004.[1]
See also
References
- Torrado S, Roig M, Farré M, Segura J, Ventura R (2008). "Urinary metabolic profile of 19-norsteroids in humans: glucuronide and sulphate conjugates after oral administration of 19-nor-4-androstenediol". Rapid Commun. Mass Spectrom. 22 (19): 3035–42. doi:10.1002/rcm.3689. PMID 18763272.
- Uralets VP, Gillette PA (2000). "Over-the-counter delta5 anabolic steroids 5-androsen-3,17-dione; 5-androsten-3beta, 17beta-diol; dehydroepiandrosterone; and 19-nor-5-androsten-3,17-dione: excretion studies in men". J Anal Toxicol. 24 (3): 188–93. doi:10.1093/jat/24.3.188. PMID 10774538.
- Earnest CP (2001). "Dietary androgen 'supplements': separating substance from hype". Phys Sportsmed. 29 (5): 63–79. doi:10.3810/psm.2001.05.781. PMID 20086575. S2CID 40760529.
ER |
| ||||||
---|---|---|---|---|---|---|---|
GPER |
| ||||||
|
PR |
| ||||||
---|---|---|---|---|---|---|---|
mPR (PAQR) |
| ||||||
|